CENTURY's AI-powered teaching and learning tool is used by leading schools across the Middle East. Our content supports the English National Curriculum and covers the essential knowledge required for PYP and MYP IB frameworks.
Explore the different ways that primary schools are using CENTURY to personalise learning, target interventions and save teachers time. Proven to increase SATs results.
South Staffordshire have been using CENTURY for five years and have fully embedded it across English and maths. Steve Wileman, Head of Digital Learning, reached out to let us know about the achievements of one of their student digital champions. We visited the college to meet their student of the year for two years running, Curtis, to congratulate him on his outstanding dedication to CENTURY ...
V116 is an investigational, 21-valent pneumococcal conjugate vaccine in Phase 3 development for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in the adult population.
V116 is the first adult specific PCV with the potential for broad public health impact through the prevention of invasive disease and pneumonia due to S. pneumoniae.
Merck has achieved a significant milestone with the approval of its investigational 21-valent pneumococcal conjugate vaccine, V116, by the US Food and Drug Administration (FDA).
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V116 compared to PPSV23 in children and teenagers 2 through 17 years of age, who had completed routine pneumococcal vaccine as infants/toddlers.
A Clinical Study of the V116 Vaccine for Children and Teenagers (V116 ...
On June 17, the US Food and Drug Administration (FDA) approved CAPVAXIVE (V116, Merck) − a 21-valent pneumococcal conjugate vaccine − to prevent invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae and pneumonia caused by S. pneumoniae in adults age 18 years and older.